TY - JOUR
T1 - An update on serum biomarkers to assess axial spondyloarthritis and to guide treatment decision
AU - Lorenzin, Mariagrazia
AU - Ometto, Francesca
AU - Ortolan, Augusta
AU - Felicetti, Mara
AU - Favero, Marta
AU - Doria, Andrea
AU - Ramonda, Roberta
PY - 2020
Y1 - 2020
N2 - Axial spondyloarthritis (axSpA) is a group of debilitating, chronic, rheumatic conditions characterized by inflammation and new bone formation, mainly involving the spine and the sacroiliac joints. The lack of biomarkers in axSpA is well known. Despite significant treatment advances in recent years thanks to the introduction of drugs with a new mode of action, such as new biologic and targeted synthetic disease-modifying antirheumatic drugs, no relevant improvement in the identification of disease biomarkers has been achieved. Common parameters, such as erythrocyte sedimentation rate and C-reactive protein, which are routinely used to measure systemic inflammation, are the sole markers available to date and are not adequate to assess disease activity in all patients. The aim of this study is to review the most promising serum biomarkers that may help treatment decision in axSpA via a proper assessment of disease activity and identification of negative prognostic factors.
AB - Axial spondyloarthritis (axSpA) is a group of debilitating, chronic, rheumatic conditions characterized by inflammation and new bone formation, mainly involving the spine and the sacroiliac joints. The lack of biomarkers in axSpA is well known. Despite significant treatment advances in recent years thanks to the introduction of drugs with a new mode of action, such as new biologic and targeted synthetic disease-modifying antirheumatic drugs, no relevant improvement in the identification of disease biomarkers has been achieved. Common parameters, such as erythrocyte sedimentation rate and C-reactive protein, which are routinely used to measure systemic inflammation, are the sole markers available to date and are not adequate to assess disease activity in all patients. The aim of this study is to review the most promising serum biomarkers that may help treatment decision in axSpA via a proper assessment of disease activity and identification of negative prognostic factors.
KW - ankylosing spondylitis
KW - anti-drug antibodies
KW - radiographic progression
KW - biomarkers
KW - disease activity
KW - axial spondyloarthritis
KW - ankylosing spondylitis
KW - anti-drug antibodies
KW - radiographic progression
KW - biomarkers
KW - disease activity
KW - axial spondyloarthritis
UR - http://hdl.handle.net/10807/305244
U2 - 10.1177/1759720X20934277
DO - 10.1177/1759720X20934277
M3 - Article
SN - 1759-720X
VL - 12
SP - N/A-N/A
JO - Therapeutic Advances in Musculoskeletal Disease
JF - Therapeutic Advances in Musculoskeletal Disease
ER -